|
Oncogenes and Tumor Suppressors
Citations 31-40 of 795 total displayed.
|
Past content
(since May 2000):
|
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets
- Uwe Rix, Oliver Hantschel, Gerhard Dürnberger, Lily L. Remsing Rix, Melanie Planyavsky, Nora V. Fernbach, Ines Kaupe, Keiryn L. Bennett, Peter Valent, Jacques Colinge, Thomas Köcher, and Giulio Superti-Furga
Blood 2007; 110: 4055-4063.
[Abstract]
[Full text]
[PDF]
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
- Deborah L. White, Verity A. Saunders, Phuong Dang, Jane Engler, Amity Venables, Stephanie Zrim, Andrew Zannettino, Kevin Lynch, Paul W. Manley, and Timothy Hughes
Blood 2007; 110: 4064-4072.
[Abstract]
[Full text]
[PDF]
The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia
- Alberto Catalano, Mark A. Dawson, Karthiga Somana, Stephen Opat, Anthony Schwarer, Lynda J. Campbell, and Harry Iland
Blood 2007; 110: 4073-4076.
[Abstract]
[Full text]
[PDF]
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
- Hagop M. Kantarjian, Francis Giles, Norbert Gattermann, Kapil Bhalla, Giuliana Alimena, Francesca Palandri, Gert J. Ossenkoppele, Franck-Emmanuel Nicolini, Stephen G. O'Brien, Mark Litzow, Ravi Bhatia, Francisco Cervantes, Ariful Haque, Yaping Shou, Debra J. Resta, Aaron Weitzman, Andreas Hochhaus, and Philipp le Coutre
Blood 2007; 110: 3540-3546.
[Abstract]
[Full text]
[PDF]
Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing
- Amy D. Klion, Jamie Robyn, Irina Maric, Weiming Fu, Laura Schmid, Steven Lemery, Pierre Noel, Melissa A. Law, Marilyn Hartsell, Cheryl Talar-Williams, Michael P. Fay, Cynthia E. Dunbar, and Thomas B. Nutman
Blood 2007; 110: 3552-3556.
[Abstract]
[Full text]
[PDF]
Aberrant mast-cell differentiation in mice lacking the stem-cell leukemia gene
- Jessica M. Salmon, Nicholas J. Slater, Mark A. Hall, Matthew P. McCormack, Stephen L. Nutt, Stephen M. Jane, and David J. Curtis
Blood 2007; 110: 3573-3581.
[Abstract]
[Full text]
[PDF]
Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome
- Andrew Chase, Francis H. Grand, and Nicholas C. P. Cross
Blood 2007; 110: 3729-3734.
[Abstract]
[Full text]
[PDF]
Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis
- Ronan Chaligné, Chloé James, Carole Tonetti, Rodolphe Besancenot, Jean Pierre Le Couédic, Fanny Fava, Fréderic Mazurier, Isabelle Godin, Karim Maloum, Frédéric Larbret, Yann Lécluse, William Vainchenker, and Stéphane Giraudier
Blood 2007; 110: 3735-3743.
[Abstract]
[Full text]
[PDF]
NOTCH1 pathway activation is an early hallmark of SCL T leukemogenesis
- Joachim R. Göthert, Rachael L. Brake, Monique Smeets, Ulrich Dührsen, C. Glenn Begley, and David J. Izon
Blood 2007; 110: 3753-3762.
[Abstract]
[Full text]
[PDF]
Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders
- Sigal Gery, Saskia Gueller, Katya Chumakova, Norihiko Kawamata, Liqin Liu, and H. Phillip Koeffler
Blood 2007; 110: 3360-3364.
[Abstract]
[Full text]
[PDF]
|
|
